Signup/Login
If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Signup/Login
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
Monitor
IPO today
Upcoming IPO
Uipath Inc (PATH)
Doubleverify Holdings, Inc. (DV)
Skywater Technology, Inc. (SKYT)
Neuropace Inc (NPCE)
Knowbe4, Inc. (KNBE)
Zymergen Inc. (ZY)
Agiliti, Inc (AGTI)
Latham Group, Inc. (SWIM)
Priced IPO
Biomea Fusion, Inc. (BMEA)
Akoya Biosciences, Inc. (AKYA)
Recursion Pharmaceuticals, Inc. (RXRX)
Karat Packaging Inc. (KRT)
AppLovin (APP)
Esports Technologies (EBET)
Agilon Health, Inc. (AGL)
TuSimple Holdings Inc (TSP)
Coinbase Global, Inc. (COIN)
Alkami Technology, Inc. (ALKT)
Reneo Pharmaceuticals, Inc. (RPHM)
Vectivbio Holding Ag (VECT)
UTime Limited (UTME)
Frontier Group Holdings (ULCC)
Compass, Inc. (COMP)
Smart Share Global Limited (EM)
Karooooo Ltd. (KARO)
Achilles Therapeutics Inc. (ACHL)
Coursera, Inc. (COUR)
Alignment Healthcare, Inc. (ALHC)
More companies

Sigilon Therapeutics, Inc. (SGTX)

Sector - Healthcare

Price chart

-4%
Return from IPO

Company News

IPO Profile

About company

They are a clinical-stage biotechnology company pioneering a new class of therapeutics and seeking to develop functional cures for patients with chronic diseases by providing stable and durable levels of therapeutic molecules to patients. They have developed their Shielded Living Therapeutics, or SLTx, platform, which combines advanced cell engineering with cutting-edge innovations in biocompatible materials and enables their product candidates to produce a wide range of therapeutic molecules that may be missing or deficient, such as proteins, antibodies and hormones. They are designing their product candidates to be off-the-shelf, durable, controllable and redosable, without requiring modification of the patient's genes or immunosuppression. Their lead product candidate, SIG-001, is designed to prevent bleeding episodes in patients with moderate-severe to severe Hemophilia A by continuously secreting human FVIII. They received acceptance of their IND submission in the United States in August 2020 and their CTA in the United Kingdom in May 2020. They have initiated their Phase 1/2 clinical study of SIG-001 in Hemophilia A, with the first patient dosed in October 2020.
Industry
Pharmaceuticals
CEO CFO
Rogerio Vivaldi Coelho Glenn Reicin
Employees Founded
2015

Contacts

Address: 100 Binney Street, Suite 600 Cambridge, Ma 02142

Telephone: (617) 336-7540

Web page: http://www.sigilon.com

IPO information

First Trade Date 12/4/2020
Status Priced
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range
-
Share prices ($)

Shares & Volumes

Shares Initial (MM) 5.6
Shares Revised (MM) 7
Expected offer amount (MM) $100.8
Realized offer amount(MM) $126

Financial Data (last reporting year)

Market Cap (MM) $518.22
Revenues (MM) $12.72
Net Income (Loss) (MM) $-54.1

Voting

What do you think will happen with the SGTX share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
The lead left underwriter: Morgan Stanley

IPOs led by the firm .Pro
Profitability of conducted IPOs  ?  .Pro
1st day change  ?  .Pro
Change for the first 3 months  ?  .Pro
Underwriters
Morgan Stanley/ Jefferies/ Barclays/ Canaccord Genuity
CO-Managers
-

Sector: Healthcare

Tweets about $SGTX

Tweets volume:

RT volume:

Timeframe:

Google Trends Stats